CAR T Cell Therapy: A Game Changer in Cancer Treatment

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Almåsbak, Hilde ^a   Aarvak, Tanja ^a   Vemuri, Mohan C ^a  

^a Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NONHUMAN; REVIEW; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); GENETIC ENGINEERING; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES; TUMOR RECURRENCE;

B-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84973169071     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/5474602     Document Type: Review

References (123)

1. G. Gross, T. Waks, and Z. Eshhar, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 10024-10028, 1989.
2. M. H. Kershaw, J. A. Westwood, L. L. Parker et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer," Clinical Cancer Research, vol. 12, no. 20, pp. 6106-6115, 2006.
3. J.H. Park and R. J. Brentjens, "Are all chimeric antigen receptors created equal?" Journal of Clinical Oncology, vol. 33, no. 6, pp. 651-653, 2015.
4. C. A. Klebanoff, L. Gattinoni, and N. P. Restifo, "Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?" Journal of Immunotherapy, vol. 35, no. 9, pp. 651-660, 2012.
5. Z. Zhao, M. Condomines, S. J. C. van der Stegen et al., "Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells," Cancer Cell, vol. 28, no. 4, pp. 415-428, 2015.
6. D. Bhutani and L. G. Lum, "Activated T cells armed with bispecific antibodies kill tumor targets," Current Opinion in Hematology, vol. 22, no. 6, pp. 476-483, 2015.
7. D. Hollyman, J. Stefanski, M. Przybylowski et al., "Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy," Journal of Immunotherapy, vol. 32, no. 2, pp. 169-180, 2009.
8. M. V. Maus and C. H. June, "Making better chimeric antigen receptors for adoptive t-cell therapy," Clinical Cancer Research, vol. 22, no. 8, pp. 1875-1884, 2016.
9. M. V. Maus, S.A. Grupp, D.L. Porter, and C.H. June, "Antibodymodified T cells: CARs take the front seat for hematologic malignancies," Blood, vol. 123, no. 17, pp. 2625-2635, 2014.
10. S. J. C. Van Der Stegen, M. Hamieh, and M. Sadelain, "The pharmacology of second-generation chimeric antigen receptors," Nature Reviews Drug Discovery, vol. 14, no. 7, pp. 499-509, 2015.
11. H. J. Kolb, J. Mittermüller, C. Clemm et al., "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients," Blood, vol. 76, no. 12, pp. 2462-2465, 1990.
12. A. Deol and L. G. Lum, "Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited," Cancer Treatment Reviews, vol. 36, no. 7, pp. 528-538, 2010.
13. S. A. Rosenberg, B. S. Packard, P. M. Aebersold et al., "Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report," The New England Journal of Medicine, vol. 319, no. 25, pp. 1676-1680, 1988.
14. M. E. Dudley, J. C. Yang, R. Sherry et al., "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens," Journal of Clinical Oncology, vol. 26, no. 32, pp. 5233-5239, 2008.
15. C. S. Hinrichs and S. A. Rosenberg, "Exploiting the curative potential of adoptive T-cell therapy for cancer," Immunological Reviews, vol. 257, no. 1, pp. 56-71, 2014.
16. + Hodgkin's disease," Journal of Experimental Medicine, vol. 200, no. 12, pp. 1623-1633, 2004.
17. J. E. Davis and D. J. Moss, "Treatment options for posttransplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies," Tissue Antigens, vol. 63, no. 4, pp. 285-292, 2004.
18. H. E. Heslop, K. S. Slobod, M. A. Pule et al., "Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBVrelated lymphoproliferative disease in transplant recipients," Blood, vol. 115, no. 5, pp. 925-935, 2010.
19. C. Yee, G. Lizee, and A. J. Schueneman, "Endogenous T-cell therapy: clinical experience," The Cancer Journal, vol. 21, no. 6, pp. 492-500, 2015.
20. D. Mezzanzanica, S. Canevari, A. Mazzoni et al., "Transfer of chimeric receptor gene made of variable regions of tumorspecific antibody confers anticarbohydrate specificity on T cells," Cancer Gene Therapy, vol. 5, no. 6, pp. 401-407, 1998.
21. C. O. Yun, K. F. Nolan, E. J. Beecham, R. A. Reisfeld, and R. P. Junghans, "Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors," Neoplasia, vol. 2, no. 5, pp. 449-459, 2000.
22. J. A. Westwood, M. J. Smyth, M. W. L. Teng et al., "Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 52, pp. 19051-19056, 2005.
23. S. Wilkie, G. Picco, J. Foster et al., "Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor," The Journal of Immunology, vol. 180, no. 7, pp. 4901-4909, 2008.
24. F. Aranda, A. Buqué, N. Bloy et al., "Trial watch: adoptive cell transfer for oncological indications," Onco Immunology, vol. 4, no. 11, Article ID e1046673, 2015.
25. C. Luo, J. Wei, and W. Han, "Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China," Science China Life Sciences, vol. 59, no. 4, pp. 349-359, 2016.
26. S. Gill and C. H. June, "Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies," Immunological Reviews, vol. 263, no. 1, pp. 68-89, 2015.
27. L. McLaughlin, C. R. Cruz, and C. M. Bollard, "Adoptive Tcell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances," Therapeutic Advances in Hematology, vol. 6, no. 6, pp. 295-307, 2015.
28. C. Berger, D. Sommermeyer, M. Hudecek et al., "Safety of targeting ROR1 in primates with chimeric antigen receptormodified T cells," Cancer Immunology Research, vol. 3, no. 2, pp. 206-216, 2015.
29. G. Dotti, S. Gottschalk, B. Savoldo, and M. K. Brenner, "Design and development of therapies using chimeric antigen receptorexpressing T cells," Immunological Reviews, vol. 257, no. 1, pp. 107-126, 2014.
30. R. O. Carpenter, M. O. Evbuomwan, S. Pittaluga et al., "B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma," Clinical Cancer Research, vol. 19, no. 8, pp. 2048-2060, 2013.
31. C. H. J. Lamers, S. Sleijfer, A. G. Vulto et al., "Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience," Journal of Clinical Oncology, vol. 24, no. 13, pp. e20-e22, 2006.
32. J. N. Kochenderfer, W. H. Wilson, J. E. Janik et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19," Blood, vol. 116, no. 20, pp. 4099-4102, 2010.
33. M. Kalos, B. L. Levine, D. L. Porter et al., "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia," Science Translational Medicine, vol. 3, no. 95, Article ID95ra73, 2011.
34. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia," The New England Journal of Medicine, vol. 365, no. 8, pp. 725-733, 2011.
35. D. L. Porter, W.-T. Hwang, N. V. Frey et al., "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia," Science Translational Medicine, vol. 7, no. 303, p. 303ra139, 2015.
36. J. A. Fraietta, K. A. Beckwith, P. R. Patel et al., "Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia," Blood, vol. 127, no. 9, pp. 1117-1127, 2016.
37. S. L. Maude, N. Frey, P. A. Shaw et al., "Chimeric antigen receptor T cells for sustained remissions in leukemia," The New England Journal of Medicine, vol. 371, no. 16, pp. 1507-1517, 2014.
38. M. L. Davila, I. Riviere, X. Wang et al., "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia," Science Translational Medicine, vol. 6, no. 224, Article ID224ra25, 2014.
39. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson et al., "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial," The Lancet, vol. 385, no. 9967, pp. 517-528, 2015.
40. W. Quasim, P. J. Amrolia, S. Samarasinghe et al., "First clinical application of Talen engineered universal CAR19 T cells in BALL," in Proceedings of the 57th Annual Meeting of the American Society of Hematology, Orlando, Fla, USA, December 2015.
41. L. P. B. Philip, C. Schiffer-Mannioui, D. Le Clerre et al., "Multiplex genome-edited T-cellmanufacturing platformfor 'off-the-shelf' adoptive T-cell immunotherapies," Cancer Research, vol. 75, no. 18, pp. 3853-3864, 2015.
42. E. Jacoby, Y. Yang, H. Qin, C. D. Chien, J. N. Kochenderfer, and T. J. Fry, "Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD," Blood, vol. 127, no. 10, pp. 1361-1370, 2016.
43. H. Dai, W. Zhang, X. Li et al., "Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia," Onco Immunology, vol. 4, no. 11, Article ID e1027469, 2015.
44. A. L. Garfall, M. V. Maus, W.-T. Hwang et al., "Chimeric antigen receptor T cells against CD19 for multiple myeloma," The New England Journal of Medicine, vol. 373, no. 11, pp. 1040-1047, 2015.
45. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim et al., "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor," Journal of Clinical Oncology, vol. 33, no. 6, pp. 540-549, 2015.
46. C. U. Louis, B. Savoldo, G. Dotti et al., "Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma," Blood, vol. 118, no. 23, pp. 6050-6056, 2011.
47. A. Morello, M. Sadelain, and P. S. Adusumilli, "Mesothelintargeted CARs: driving t cells to solid tumors," Cancer Discovery, vol. 6, no. 2, pp. 133-146, 2016.
48. L. M. Whilding and J. Maher, "ErbB-targeted CAR T-cell immunotherapy of cancer," Immunotherapy, vol. 7, no. 3, pp. 229-241, 2015.
49. S. Scholl, P. Beuzeboc, and P. Pouillart, "Targeting HER2 in other tumor types," Annals of Oncology, vol. 12, supplement 1, pp. S81-S87, 2001.
50. N. Ahmed, V. S. Brawley, M. Hegde et al., "Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma," Journal of Clinical Oncology, vol. 33, no. 15, pp. 1688-1696, 2015.
51. K. Feng, Y. Guo, H. Dai et al., "Chimeric antigen receptormodified T cells for the immunotherapy of patients with EGFRexpressing advanced relapsed/refractory non-small cell lung cancer," Science China Life Sciences, vol. 59, no. 5, pp. 468-479, 2016.
52. J. Sun, L. E. Huye, N. Lapteva et al., "Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application," Journal for Immuno Therapy of Cancer, vol. 3, no. 1, article 5, 2015.
53. S. Kakarla, K. K. H. Chow, M. Mata et al., "Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma," Molecular Therapy, vol. 21, no. 8, pp. 1611-1620, 2013.
54. D. Chinnasamy, E. Tran, Z. Yu, R. A. Morgan, N. P. Restifo, and S. A. Rosenberg, "Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice," Cancer Research, vol. 73, no. 11, pp. 3371-3380, 2013.
55. + liver metastases," Clinical Cancer Research, vol. 21, no. 14, pp. 3149-3159, 2015.
56. G. L. Beatty, A. R. Haas, M. V. Maus et al., "Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies," Cancer Immunology Research, vol. 2, no. 2, pp. 112-120, 2014.
57. F. You, L. Jiang, B. Zhang et al., "Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells," Science China Life Sciences, vol. 59, no. 4, pp. 386-397, 2016.
58. B. Savoldo, C. A. Ramos, E. Liu et al., "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients," Journal of Clinical Investigation, vol. 121, no. 5, pp. 1822-1826, 2011.
59. A.H. Long, W. M. Haso, J. F. Shern et al., "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors," Nature Medicine, vol. 21, no. 6, pp. 581-590, 2015.
60. M. A. Pulè, K.C. Straathof, G. Dotti, H.E. Heslop, C.M. Rooney, and M. K. Brenner, "A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells," Molecular Therapy, vol. 12, no. 5, pp. 933-941, 2005.
61. M. C. Milone, J. D. Fish, C. Carpenito et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo," Molecular Therapy, vol. 17, no. 8, pp. 1453-1464, 2009.
62. + T cell-mediated tumor eradication," Molecular Therapy, vol. 18, no. 2, pp. 413-420, 2010.
63. S. Tammana, X. Huang, M. Wong et al., "4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood t cells against b-cellmalignancies," Human Gene Therapy, vol. 21, no. 1, pp. 75-86, 2010.
64. H. Karlsson, E. Svensson, C. Gigg et al., "Evaluation of intracellular signaling downstream chimeric antigen receptors," PLoS ONE, vol. 10, no. 12, Article ID e0144787, 2015.
65. B. G. Till, M. C. Jensen, J. Wang et al., "CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results," Blood, vol. 119, no. 17, pp. 3940-3950, 2012.
66. N. P. Weng, "Telomeres and immune competency," Current Opinion in Immunology, vol. 24, no. 4, pp. 470-475, 2012.
67. + T cells derived from central memory cells establishes persistent T cell memory in primates," The Journal of Clinical Investigation, vol. 118, no. 1, pp. 294-305, 2008.
68. H. Almåsbak, M. Lundby, and A.-M. Rasmussen, "Non-MHCdependent redirected T cells against tumor cells," Methods in Molecular Biology, vol. 629, pp. 453-493, 2010.
69. S. R. Riddell, D. Sommermeyer, C. Berger et al., "Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition," Cancer Journal, vol. 20, no. 2, pp. 141-144, 2014.
70. + subsets confer superior antitumor reactivity in vivo," Leukemia, vol. 30, no. 2, pp. 492-500, 2016.
71. L. Gattinoni, E. Lugli, Y. Ji et al., "Ahumanmemory T cell subset with stem cell-like properties," Nature Medicine, vol. 17, no. 10, pp. 1290-1297, 2011.
72. N. Cieri, B. Camisa, F. Cocchiarella et al., "IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors," Blood, vol. 121, no. 4, pp. 573-584, 2013.
73. P. Muranski, Z. A. Borman, S.P. Kerkar et al., "Th17 cells are long lived and retain a stemcell-like molecular signature," Immunity, vol. 35, no. 6, pp. 972-985, 2011.
74. H17 cells," Science Translational Medicine, vol. 2, no. 55, Article ID 55ra78, 2010.
75. S. Guedan, X. Chen, A. Madar et al., "ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells," Blood, vol. 124, no. 7, pp. 1070-1080, 2014.
76. J. S. Bowers, M. H. Nelson, S. Kundimi et al., "Dendritic cells in irradiated mice trigger the functional plasticity and antitumor activity of adoptively transferred Tc17 cells via IL12 signaling," Clinical Cancer Research, vol. 21, no. 11, pp. 2546-2557, 2015.
77. M.A. Pule, B. Savoldo, G. D. Myers et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma," Nature Medicine, vol. 14, no. 11, pp. 1264-1270, 2008.
78. C. Rossig, C. M. Bollard, J. G. Nuchtern, C.M. Rooney, and M. K. Brenner, "Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy," Blood, vol. 99, no. 6, pp. 2009-2016, 2002.
79. + T cells derived from virusspecific central memory T cells," Blood, vol. 119, no. 1, pp. 72-82, 2012.
80. C. A. Klebanoff, H. T. Khong, P. A. Antony, D. C. Palmer, and N. P. Restifo, "Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy," Trends in Immunology, vol. 26, no. 2, pp. 111-117, 2005.
81. E. Sotillo, D. M. Barrett, K. L. Black et al., "Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy," Cancer Discovery, vol. 5, no. 12, pp. 1282-1295, 2015.
82. Z. Grada, M. Hegde, T. Byrd et al., "TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy," Molecular Therapy-Nucleic Acids, vol. 2, article e105, 2013.
83. G. L. Beatty and E. K. Moon, "Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment," Oncoimmunology, vol. 3, no. 11, Article ID e970027, 2014.
84. D. E. Gilham, R. Debets, M. Pule, R. E. Hawkins, and H. Abken, "CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe," Trends in Molecular Medicine, vol. 18, no. 7, pp. 377-384, 2012.
85. S. Kakarla and S. Gottschalk, "CAR T cells for solid tumors: armed and ready to go?" Cancer Journal, vol. 20, no. 2, pp. 151-155, 2014.
86. L. M. Whilding and J. Maher, "CAR T-cell immunotherapy: the path fromthe by-road to the freeway?" Molecular Oncology, vol. 9, no. 10, pp. 1994-2018, 2015.
87. M. Chmielewski and H. Abken, "TRUCKs: the fourth generation of CARs," Expert Opinion on Biological Therapy, vol. 15, no. 8, pp. 1145-1154, 2015.
88. H. J. Pegram, J. H. Park, and R. J. Brentjens, "CD28z CARs and armored CARs," Cancer Journal, vol. 20, no. 2, pp. 127-133, 2014.
89. M. A. Ligtenberg, D. Mougiakakos, M. Mukhopadhyay et al., "Coexpressed catalase protects chimeric antigen receptorredirected t cells as well as bystander cells fromoxidative stressinduced loss of antitumor activity," The Journal of Immunology, vol. 196, no. 2, pp. 759-766, 2016.
90. I. Caruana, B. Savoldo, V. Hoyos et al., "Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes," Nature Medicine, vol. 21, no. 5, pp. 524-529, 2015.
91. L. B. John, C. Devaud, C. P.M. Duong et al., "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells," Clinical Cancer Research, vol. 19, no. 20, pp. 5636-5646, 2013.
92. X. Liu, R. Ranganathan, S. Jiang et al., "A chimeric switchreceptor targeting pd1 augments the efficacy of secondgeneration CAR T cells in advanced solid tumors," Cancer Research, vol. 76, no. 6, pp. 1578-1590, 2016.
93. S. Kobold, S. Grassmann, M. Chaloupka et al., "Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy," Journal of the National Cancer Institute, vol. 107, no. 8, 2015.
94. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain, "Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: Case report of an unforeseen adverse event in a phase I clinical trial," Molecular Therapy, vol. 18, no. 4, pp. 666-668, 2010.
95. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C.M. Laurencot, and S. A. Rosenberg, "Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2," Molecular Therapy, vol. 18, no. 4, pp. 843-851, 2010.
96. J. N. Kochenderfer, M. E. Dudley, S. A. Feldman et al., "B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimericantigen-receptor-transduced T cells," Blood, vol. 119, no. 12, pp. 2709-2720, 2012.
97. D. W. Lee, R. Gardner, D. L. Porter et al., "Current concepts in the diagnosis and management of cytokine release syndrome," Blood, vol. 124, no. 2, pp. 188-195, 2014.
98. S. A. Grupp, M. Kalos, D. Barrett et al., "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia," The New England Journal of Medicine, vol. 368, no. 16, pp. 1509-1518, 2013.
99. X. Liu, S. Jiang, C. Fang et al., "Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice," Cancer Research, vol. 75, no. 17, pp. 3596-3607, 2015.
100. S. Wilkie, M. C. I. van Schalkwyk, S. Hobbs et al., "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling," Journal of Clinical Immunology, vol. 32, no. 5, pp. 1059-1070, 2012.
101. C. C. Kloss, M. Condomines, M. Cartellieri, M. Bachmann, and M. Sadelain, "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells," Nature Biotechnology, vol. 31, no. 1, pp. 71-75, 2013.
102. E. Lanitis, M. Poussin, A. W. Klattenhoff et al., "Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo," Cancer Immunology Research, vol. 1, no. 1, pp. 43-53, 2013.
103. V. D. Fedorov, M. Themeli, and M. Sadelain, "PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses," Science Translational Medicine, vol. 5, no. 215, Article ID 215ra172, 2013.
104. D. T. Rodgers, M. Mazagova, E. N. Hampton et al., "Switchmediated activation and retargeting of CAR-T cells for B-cell malignancies," Proceedings of the National Academy of Sciences, vol. 113, no. 4, pp. E459-E468, 2016.
105. A. Juillerat, A. Marechal, J. M. Filhol et al., "Design of chimeric antigen receptors with integrated controllable transient functions," Scientific Reports, vol. 6, article 18950, 2016.
106. J. S. Ma, J. Y. Kim, S. A. Kazane et al., "Versatile strategy for controlling the specificity and activity of engineered T cells," Proceedings of the National Academy of Sciences, vol. 113, no. 4, pp. E450-E458, 2016.
107. M. Pule, C. M. Bollard, and H. E. Heslop, "Genetically engineered T-cells for adoptive immunotherapy," Current Opinion in Molecular Therapeutics, vol. 4, no. 5, pp. 467-475, 2002.
108. B. S. Jones, L. S. Lamb, F. Goldman, and A. Di Stasi, "Improving the safety of cell therapy products by suicide gene transfer," Frontiers in Pharmacology, vol. 5, p. 254, 2014.
109. V. Marin, E. Cribioli, B. Philip et al., "Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells," Human Gene Therapy Methods, vol. 23, no. 6, pp. 376-386, 2012.
110. X. Wang, W.-C. Chang, C.W. Wong et al., "Atransgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells," Blood, vol. 118, no. 5, pp. 1255-1263, 2011.
111. B. Philip, E. Kokalaki, L. Mekkaoui et al., "A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy," Blood, vol. 124, no. 8, pp. 1277-1287, 2014.
112. H. Almåsbak, E. Walseng, A. Kristian et al., "Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model," Gene Therapy, vol. 22, no. 5, pp. 391-403, 2015.
113. 8+ T cells for use in the adoptive immunotherapy of cancer," Gene Therapy, vol. 16, no. 5, pp. 596-604, 2009.
114. C. H. J. Lamers, S. Sleijfer, S. van Steenbergen et al., "Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity," Molecular Therapy, vol. 21, no. 4, pp. 904-912, 2013.
115. M. Cavazzana-Calvo, A. Fischer, S. Hacein-Bey-Abina, and A. Aiuti, "Gene therapy for primary immunodeficiencies: part 1," Current Opinion in Immunology, vol. 24, no. 5, pp. 580-584, 2012.
116. J. Scholler, T. L. Brady, G. Binder-Scholl et al., "Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells," Science Translational Medicine, vol. 4, no. 132, Article ID 132ra53, 2012.
117. S. Newrzela, K. Cornils, Z. Li et al., "Resistance ofmature T cells to oncogene transformation," Blood, vol. 112, no. 6, pp. 2278-2286, 2008.
118. D. M. Barrett, S. A. Grupp, and C. H. June, "Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street," Journal of Immunology, vol. 195, no. 3, pp. 755-761, 2015.
119. H. Dai, Y. Wang, X. Lu, and W. Han, "Chimeric antigen receptors modified T-cells for cancer therapy," Journal of the National Cancer Institute, vol. 108, no. 7, Article IDdjv439, 2016.
120. A. D. Kaiser, M. Assenmacher, B. Schröder et al., "Towards a commercial process for themanufacture of geneticallymodified T cells for therapy," Cancer Gene Therapy, vol. 22, no. 2, pp. 72-78, 2015.
121. B. L. Levine and C. H. June, "Perspective: assembly line immunotherapy," Nature, vol. 498, no. 7455, p. S17, 2013.
122. A. Walker and R. Johnson, "Commercialization of cellular immunotherapies for cancer," Biochemical Society Transactions, vol. 44, no. 2, pp. 329-332, 2016.
123. R. A. Morgan and S. Kakarla, "Genetic modification of T cells," Cancer Journal, vol. 20, no. 2, pp. 145-150, 2014.